Charles Jensen, Ph.D., has been appointed director of Drug Metabolism and Pharmacokinetics (DMPK) at AMRI. He reports to Bruce J. Sargent, Ph.D., senior vice president of Drug Discovery.

Dr. Jensen has more than 20 years of experience working in the fields of drug metabolism and toxicology in the pharmaceutical industry. He spent 15 years at Eli Lilly and Co., where he ultimately became senior study director for drug development services for in vitro technologies. Prior to Lilly, Dr. Jensen worked for RTI Health Solutions, where he established a full-service in vitro DMPK-toxicology lab and developed a robust intestinal permeability/Pgp transport model.

“At AMRI, we consider early ADMET profiling and pharmacokinetic analysis to be crucial components of the drug discovery process, and we are excited to have Dr. Jensen join us with his substantial experience in these fields. His DMPK expertise adds additional depth to AMRI’s leading drug discovery team and will help position the company as it expands its involvement with fully integrated discovery biology and chemistry programs,” said Dr. Sargent.